Compare Cipla with IPCA Labs - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs IPCA LABS - Comparison Results

CIPLA     Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA IPCA LABS CIPLA/
IPCA LABS
 
P/E (TTM) x 33.3 32.1 103.8% View Chart
P/BV x 3.4 6.7 51.2% View Chart
Dividend Yield % 0.5 0.2 259.7%  

Financials

 CIPLA   IPCA LABS
EQUITY SHARE DATA
    CIPLA
Mar-19
IPCA LABS
Mar-19
CIPLA/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs6781,042 65.1%   
Low Rs484590 82.0%   
Sales per share (Unadj.) Rs198.2298.6 66.4%  
Earnings per share (Unadj.) Rs18.535.0 52.9%  
Cash flow per share (Unadj.) Rs35.049.4 70.8%  
Dividends per share (Unadj.) Rs3.003.00 100.0%  
Dividend yield (eoy) %0.50.4 140.5%  
Book value per share (Unadj.) Rs186.3247.1 75.4%  
Shares outstanding (eoy) m805.70126.35 637.7%   
Bonus/Rights/Conversions ESOPESOS-  
Price / Sales ratio x2.92.7 107.2%   
Avg P/E ratio x31.423.3 134.5%  
P/CF ratio (eoy) x16.616.5 100.6%  
Price / Book Value ratio x3.13.3 94.4%  
Dividend payout %16.28.6 188.9%   
Avg Mkt Cap Rs m468,031103,108 453.9%   
No. of employees `00022.613.4 168.5%   
Total wages/salary Rs m28,5657,874 362.8%   
Avg. sales/employee Rs Th7,053.12,807.0 251.3%   
Avg. wages/employee Rs Th1,261.5585.8 215.4%   
Avg. net profit/employee Rs Th659.1329.0 200.3%   
INCOME DATA
Net Sales Rs m159,71037,732 423.3%  
Other income Rs m4,766577 826.2%   
Total revenues Rs m164,47538,309 429.3%   
Gross profit Rs m30,9736,901 448.8%  
Depreciation Rs m13,2631,824 727.1%   
Interest Rs m1,684189 892.6%   
Profit before tax Rs m20,7915,465 380.5%   
Minority Interest Rs m-1720-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5,6951,042 546.4%   
Profit after tax Rs m14,9244,422 337.5%  
Gross profit margin %19.418.3 106.0%  
Effective tax rate %27.419.1 143.6%   
Net profit margin %9.311.7 79.7%  
BALANCE SHEET DATA
Current assets Rs m124,26623,778 522.6%   
Current liabilities Rs m37,71510,975 343.6%   
Net working cap to sales %54.233.9 159.7%  
Current ratio x3.32.2 152.1%  
Inventory Days Days91104 87.3%  
Debtors Days Days9566 143.9%  
Net fixed assets Rs m105,19020,368 516.5%   
Share capital Rs m1,611253 637.7%   
"Free" reserves Rs m148,51130,971 479.5%   
Net worth Rs m150,12331,224 480.8%   
Long term debt Rs m38,3011,409 2,719.3%   
Total assets Rs m239,63345,507 526.6%  
Interest coverage x13.330.0 44.5%   
Debt to equity ratio x0.30 565.6%  
Sales to assets ratio x0.70.8 80.4%   
Return on assets %6.910.1 68.4%  
Return on equity %9.914.2 70.2%  
Return on capital %11.817.3 68.3%  
Exports to sales %34.745.9 75.6%   
Imports to sales %016.6 0.0%   
Exports (fob) Rs m55,41917,308 320.2%   
Imports (cif) Rs mNA6,266 0.0%   
Fx inflow Rs m57,41017,308 331.7%   
Fx outflow Rs m19,0416,266 303.9%   
Net fx Rs m38,36811,042 347.5%   
CASH FLOW
From Operations Rs m16,9114,923 343.5%  
From Investments Rs m-16,687-1,563 1,067.5%  
From Financial Activity Rs m-3,487-1,832 190.3%  
Net Cashflow Rs m-3,4511,528 -225.9%  

Share Holding

Indian Promoters % 16.0 45.9 34.9%  
Foreign collaborators % 20.8 0.0 -  
Indian inst/Mut Fund % 12.2 11.4 107.0%  
FIIs % 23.7 25.3 93.7%  
ADR/GDR % 1.1 0.0 -  
Free float % 26.2 17.4 150.6%  
Shareholders   161,166 36,892 436.9%  
Pledged promoter(s) holding % 0.0 2.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   PFIZER  GSK PHARMA  DR. DATSONS LABS  PROCTER & GAMBLE HEALTH  NOVARTIS  

Compare CIPLA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Falls 750 Points from Day's High; Telecom and Energy Stocks Witness Selling(Closing)

After opening the day on a strong note, Indian share markets witnessed selling pressure during closing hours today and ended flat.

Related Views on News

CIPLA Announces Quarterly Results (4QFY20); Net Profit Down 35.1% (Quarterly Result Update)

May 19, 2020 | Updated on May 19, 2020

For the quarter ended March 2020, CIPLA has posted a net profit of Rs 2 bn (down 35.1% YoY). Sales on the other hand came in at Rs 44 bn (down 0.6% YoY). Read on for a complete analysis of CIPLA's quarterly results.

IPCA LABS Announces Quarterly Results (3QFY20); Net Profit Up 22.8% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, IPCA LABS has posted a net profit of Rs 2 bn (up 22.8% YoY). Sales on the other hand came in at Rs 11 bn (up 20.2% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

CIPLA Announces Quarterly Results (3QFY20); Net Profit Up 9.4% (Quarterly Result Update)

Feb 6, 2020 | Updated on Feb 6, 2020

For the quarter ended December 2019, CIPLA has posted a net profit of Rs 4 bn (up 9.4% YoY). Sales on the other hand came in at Rs 44 bn (up 9.1% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (2QFY20); Net Profit Up 31.2% (Quarterly Result Update)

Nov 14, 2019 | Updated on Nov 14, 2019

For the quarter ended September 2019, CIPLA has posted a net profit of Rs 5 bn (up 31.2% YoY). Sales on the other hand came in at Rs 44 bn (up 9.6% YoY). Read on for a complete analysis of CIPLA's quarterly results.

IPCA LABS Announces Quarterly Results (2QFY20); Net Profit Up 63.7% (Quarterly Result Update)

Nov 12, 2019 | Updated on Nov 12, 2019

For the quarter ended September 2019, IPCA LABS has posted a net profit of Rs 2 bn (up 63.7% YoY). Sales on the other hand came in at Rs 12 bn (up 21.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

More Views on News

Most Popular

How to Find the Best Stocks for Day Trading - 1(Fast Profits Daily)

Jul 2, 2020

In the first of two videos, I'll show you how to identify the best stocks for intraday trading.

Two Agri Stocks Are Likely to Outperform Even in this Market(Profit Hunter)

Jul 2, 2020

Why we have recommended two agriculture stocks for our Hidden Treasure subscribers. Read on...

Smallcaps Are in a Sweet Spot Again: Are You Buying?(Profit Hunter)

Jul 3, 2020

This is why I believe smallcaps are the place to be in the near future.

How We Made 10%+ Profits Overnight(Fast Profits Daily)

Jul 3, 2020

A simple trade in natural gas delivered more than 10% overnight. Here's how we did it...

More

India's #1 Trader
Reveals His Secrets

The Secret to Increasing Your Trading Profits Today
Get this Special Report, The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Jul 15, 2020 03:35 PM

TRACK CIPLA

COMPARE CIPLA WITH

MARKET STATS